Pradaxa is a brand name for dabigatran, a drug belonging to the direct thrombin inhibitor class.
Here’s a list of Pradaxa prices:
The medication was developed by Boehringer Ingelheim. On 19 October 2010, the Food and Drug Administration approved its use for the prevention of stroke in patients diagnosed with non-valvular atrial fibrillation.
Pradaxa is an oral anticoagulant drug used for medical uses including:
- The prevention of strokes in patients with atrial fibrillation but unrelated to heart valve issues; and
- The prevention of pulmonary embolism and deep vein thrombosis in patients who have undergone treatment with a parenteral anticoagulant for 5 to 10 days, as well as in other circumstances.
Studies appear to show that it may be as effective as warfarin, also an anticoagulant drug, even as an alternative. This is because its proper use can yield similar results but without the necessity for monitoring via blood tests.
Pradaxa isn’t recommended for patients with active pathological bleeding, a previous occurrence of hypersensitive reaction to dabigatran, and with a prosthetic heart valve. The drug can increase the risk for potentially life-threatening bleeding, as well as stroke, valve thrombosis, and myocardial infarction.
The most common side of use is an upset stomach (i.e., minor gastrointestinal issues). But in comparison with the use of warfarin, patients on dabigatran reported fewer bleeding instances including intracranial bleeds.
Patients with poor kidney function should be given reduced doses. Due to the risks involved, the use of Pradaxa should be recommended and monitored by a qualified doctor. The prescribed dosage, frequency and duration of treatment should also be followed for best results.